Financial Engines Advisors
AQST icon

Financial Engines Advisors’s Aquestive Therapeutics AQST Stock Holding History

Financial Engines Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$423K Buy
101,793
+4,310
+4% +$18.1K ﹤0.01% 435
2026
Q1 		$405K Hold
97,483
– – ﹤0.01% 420
2025
Q4 		$630K Buy
97,483
+1,730
+2% +$10.8K ﹤0.01% 366
2025
Q3 		$535K Sell
95,753
-176,933
-65% -$765K ﹤0.01% 382
2025
Q2 		$903K Buy
+272,686
New +$782K ﹤0.01% 304

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Financial Engines Advisors's AQST Position: Q2 2026 in Review

Financial Engines Advisors increased its Aquestive Therapeutics (AQST) stake by 4.4% in Q2 2026, buying an estimated $18.1K and bringing the position to 101,793 shares worth $423K. The position accounts for ﹤0.01% of the portfolio, ranked #435.

Financial Engines Advisors first reported a position in AQST in Q2 2025 and has held it in 5 quarters since. The position peaked at $903K in Q2 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Financial Engines Advisors held 101,793 shares of Aquestive Therapeutics worth $423K as of Q2 2026.
  • Financial Engines Advisors bought 4,310 Aquestive Therapeutics shares in Q2 2026, an estimated $18.1K.
  • Aquestive Therapeutics made up ﹤0.01% of Financial Engines Advisors's portfolio in Q2 2026, its #435 holding.
  • Financial Engines Advisors first reported a position in Aquestive Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Financial Engines Advisors's Aquestive Therapeutics position peaked at $903K in Q2 2025.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Financial Engines Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.